Table 1: Literature with differing clinical courses.
|
No |
Age |
Sex |
KPS |
CD4 (/μl) |
LDH (U/L) |
cART |
Pathology |
CD20 |
Mib1 |
EBV |
CTX |
RTX |
F/U(months) |
O |
|
1 |
41 |
M |
90 |
77 |
199 |
DRV+RTV+ETR |
DLBCL |
+ |
60 |
+ |
- |
60 Gy |
145 |
S |
|
2 |
67 |
M |
70 |
3 |
192 |
ABC+3TC+FPV |
DLBCL |
+ |
NA |
+ |
- |
23 Gy |
2 |
D |
|
3 |
37 |
M |
50 |
5 |
278 |
ABC+3TC+FPV |
DLBCL |
+ |
80 |
+ |
R-HDMTX |
- |
127 |
S |
|
4 |
36 |
M |
20 |
10 |
150 |
ABC+3TC+RAL |
DLBCL |
+ |
NA |
+ |
- |
50 Gy |
10 |
D |
|
5 |
52 |
M |
70 |
5 |
171 |
DRV+RTV+TDF/FTC |
DLBCL |
+ |
100 |
+ |
R |
36 Gy |
19 |
D |
|
6 |
28 |
M |
80 |
66 |
247 |
ABC+3TC+RAL |
DLBCL |
+ |
50 |
- |
R-HDMTX |
- |
84 |
S |
Abbreviations - 3TC: Lamivudine; ABC: Abacavir; cART: Combination antiretroviral therapy; CTX: Chemotherapy; D: Death; DLBCL: Diffuse large B cell lymphoma; DRV: Darunavir; Dx: Diagnosis; EBV: Epstein burr virus; ETR: Etravirine; F/U: Follow up; FPV: Fosamprenavir; FTC: Emtricabine; HDMTX: High dose methotrexate; KPS: Karnofsky performance status; NA: Not available; R: Rituximab; OS: Overall survival; P: Pathology; RAL: Raltegravir; RTV: Ritonavir; RTX: Radiotherapy; S: Survive; TDF: Tenofovir